Osteopathia striata-pigmentary dermopathy-white forelock syndrome

disease
On this page

Also known as osteopathia striata associated with familial dermopathy and white forelockosteopathia striata with pigmentary dermopathy including white forelockWhyte Murphy syndromeWhyte-Murphy syndrome

Summary

Osteopathia striata-pigmentary dermopathy-white forelock syndrome (MONDO:0017197) is a disease. A subtype of hyperpigmentation of the skin — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
  • Phenotypes (HPO): 7

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Cases/families3WorldwideValidated
Point prevalence<1 / 1 000 000WorldwideValidated

Signs & symptoms

Clinical features (HPO)

7 HPO clinical features (Orphanet curated; top 7 by frequency):

HPO IDTermFrequency
HP:0000940Abnormal diaphysis morphologyVery frequent (80-99%)
HP:0000944Abnormal metaphysis morphologyVery frequent (80-99%)
HP:0002211White forelockVery frequent (80-99%)
HP:0002644Abnormality of pelvic girdle bone morphologyVery frequent (80-99%)
HP:0007412Macular hyperpigmented dermopathyVery frequent (80-99%)
HP:0010740Osteopathia striataVery frequent (80-99%)
HP:0100670Rough bone trabeculationVery frequent (80-99%)

Identifiers

Disease identifiers

FieldValue
Canonical nameosteopathia striata-pigmentary dermopathy-white forelock syndrome
Mondo IDMONDO:0017197
MeSHC536054
Orphanet2779
UMLSC2931096
MedGen419711
GARD0005562
Is cancer (heuristic)no

Also known as: osteopathia striata associated with familial dermopathy and white forelock · osteopathia striata with pigmentary dermopathy including white forelock · Whyte Murphy syndrome · Whyte-Murphy syndrome

Disease family

This is a subtype of hyperpigmentation of the skin. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorderskin pigmentation disorderhyperpigmentation of the skinosteopathia striata-pigmentary dermopathy-white forelock syndrome

Related subtypes (23): dyschromatosis universalis hereditaria, cafe au lait spots, multiple, dermatopathia pigmentosa reticularis, dyschromatosis symmetrica hereditaria, extrasystoles-short stature-hyperpigmentation-microcephaly syndrome, gastrocutaneous syndrome, hyperkeratosis-hyperpigmentation syndrome, familial generalized lentiginosis, Naegeli-Franceschetti-Jadassohn syndrome, schwannomatosis, Dowling-Degos disease, H syndrome, Legius syndrome, familial progressive hyperpigmentation, linear and whorled nevoid hypermelanosis, reticulate acropigmentation of Kitamura, nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome, severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome, leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome, phakomatosis pigmentovascularis, acromelanosis, hyperpigmentation, progressive cribriform and zosteriform, mosaic Legius syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.